These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
93 related items for PubMed ID: 11971067
1. Interferon beta-1a treatment of corticosteroid sensitive polymyositis. Dressel A, Beuche W. J Neurol Neurosurg Psychiatry; 2002 May; 72(5):676. PubMed ID: 11971067 [No Abstract] [Full Text] [Related]
2. The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis. Leary SM, Thompson AJ. J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):508-9. PubMed ID: 14966181 [No Abstract] [Full Text] [Related]
3. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Francis G, Weber F, Rieckmann P. Neurology; 2000 Jul 25; 55(2):322-3. PubMed ID: 10908925 [No Abstract] [Full Text] [Related]
8. Interferon-beta: a novel way to treat nephrotic syndrome? Rees AJ, Kain R. J Am Soc Nephrol; 2007 Nov 25; 18(11):2797-8. PubMed ID: 17942945 [No Abstract] [Full Text] [Related]
11. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. Lee SW, Kim KC, Oh DH, Jung SS, Yoo DH, Kim SY, Choe G, Kim TH. J Korean Med Sci; 2002 Feb 25; 17(1):141-3. PubMed ID: 11850606 [Abstract] [Full Text] [Related]
12. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group. Lancet Neurol; 2011 Jun 25; 10(6):520-9. PubMed ID: 21571593 [Abstract] [Full Text] [Related]
13. Inhibitory effect of human interferon-beta-1a on activated rat and human hepatic stellate cells. Rao HY, Wei L, Wang JH, Fei R, Jiang D, Zhang Q, Chen HS, Cong X. J Gastroenterol Hepatol; 2010 Nov 25; 25(11):1777-84. PubMed ID: 21039841 [Abstract] [Full Text] [Related]
15. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al]. Labetouelle M. J Fr Ophtalmol; 2001 Feb 25; 24(2):222. PubMed ID: 11332406 [No Abstract] [Full Text] [Related]
16. Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study. Goebel MU, Czolbe F, Becker H, Janssen OE, Schedlowski M, Limmroth V. Eur Neurol; 2005 Feb 25; 53(4):182-7. PubMed ID: 15947464 [Abstract] [Full Text] [Related]
17. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. Williams GJ, Witt PL. J Interferon Cytokine Res; 1998 Nov 25; 18(11):967-75. PubMed ID: 9858319 [Abstract] [Full Text] [Related]
18. [Effectiveness of betaserk in vestibular disorders]. Abdulkerimov KhT, Markov IS, Usachev VI. Zh Nevrol Psikhiatr Im S S Korsakova; 2002 Nov 25; 102(6):50-2. PubMed ID: 12101896 [No Abstract] [Full Text] [Related]
19. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis. Christopher V, Scolding N, Przemioslo RT. J Neurol; 2005 Jul 25; 252(7):855-6. PubMed ID: 15742101 [No Abstract] [Full Text] [Related]
20. [Treatment of polymyositis and dermatomyositis]. Chérin P. Rev Med Interne; 2004 Jun 25; 25 Suppl 1():S22-5. PubMed ID: 15165688 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]